Challenging Cases from the Clinic: The Treatment-Experienced Patient
CME Released: 09/21/2011; Valid for credit through 09/21/2012
Quick Links
| Overview | Accreditation Statement |
| Learning Objectives | Additional Information |
| Authors and Disclosures |
Overview
As part of the Clinical Course in Viral Hepatitis planned series, an educational collaboration between MedscapeCME and the AGA Institute, this activity is targeted at providing clinicians who manage viral hepatitis with timely, comprehensive medical education in a variety of learning formats.
This activity will address practice gaps in hepatitis C virus (HCV) screening, diagnosis, referral and treatment, and help change the course of the urgent public crisis of undiagnosed and untreated chronic HCV infection.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Identify and address the needs of more complex patients with chronic HCV infection.
- Determine candidacy and develop individualized strategies for treatment of chronic HCV infection.
- Individualize treatment based on virologic response.
- Evaluate the clinical implications of new data on treatment options for patients with chronic HCV infection.
Author and Disclosure
As organizations accredited by the ACCME, AGA Institute and Medscape, LLC require everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest.
Author
David Berstein, MD
Professor of Clinical Medicine, Albert Einstein School of Medicine, Bronx, New York; Chief, Digestive Disease Institute, Division of Gastroenterology, Hepatology, and Nutrition, North Shore University Hospital/Long Island Jewish Medical Center, Manhasset, New York
Disclosure
- Received grants for clinical research from Genentech, Inc.; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated
- Served as an advisor or consultant for Merck & Co. Inc.; Vertex Pharmaceuticals Incorporated
- Served as a speaker or member of a speakers bureau for Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated
Dr. Bernstein does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the U.S. Food and Drug Administration (FDA) for use in the United States.
Dr. Bernstein does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the United States.
Editor
Susan L. Smith, MN, PhD
Senior Scientific Director, Medscape, LLC
No relevant financial relationships disclosed.
CME Reviewer
Nafeez Zawahir, MD
CME Clinical Director, Medscape, LLC
No relevant financial relationships disclosed.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity
Additional Information
For questions regarding the content of this activity, contact the accredited provider for the CME/CE activity noted above. For technical assistance, contact CME@medscape.net.
